Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 5/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12385794 | 1.00 | ALDH1A1 (0.58) | ALDH1A1LMNAHPGDKDM4EGAA | |
| SCHEMBL8414750 | 1.00 | ALDH1A1 (0.58) | ALDH1A1LMNAHPGDKDM4EGAA | |
| SCHEMBL15014482 | 0.94 | ALDH1A1 (0.56) | ALDH1A1LMNAHPGDKDM4EGAA | |
| SCHEMBL15014599 | 0.94 | ALDH1A1 (0.56) | ALDH1A1LMNAHPGDKDM4EGAA | |
| SCHEMBL13212406 | 0.94 | ALDH1A1 (0.56) | ALDH1A1LMNAHPGDKDM4EGAA | |
| SCHEMBL14879739 | 0.92 | ALDH1A1 (0.59) | ALDH1A1LMNAHPGDKDM4EGAA | |
| SCHEMBL17907464 | 0.91 | ALDH1A1 (0.50) | ALDH1A1LMNAHPGDKDM4EGAA | |
| SCHEMBL22500126 | 0.89 | ALDH1A1 (0.59) | ALDH1A1LMNAHPGDKDM4EGAA | |
| SCHEMBL15014596 | 0.88 | ALDH1A1 (0.48) | ALDH1A1LMNAHPGDKDM4EGAA | |
| SCHEMBL15014572 | 0.88 | ALDH1A1 (0.48) | ALDH1A1LMNAHPGDKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324199-B2 | Pyridazine derivatives as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | claimed |
| EP-2265601-B1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-02-01 | — | — | EP | claimed |
| US-20110021492-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-27 | — | — | US | claimed |
| EP-2265601-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2010-12-29 | — | — | EP | claimed |
| WO-2009114677-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-17 | — | — | WO | claimed |
| EP-4289823-A1 | SUBSTITUTED PYRIDAZINE PHENOL DERIVATIVES | Medshine Discovery Inc. (CN) | 2023-12-13 | — | — | EP | disclosed |
| WO-2022048684-A1 | JNK INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 武汉朗来科技发展有限公司 | 2022-03-10 | — | — | WO | disclosed |
| EP-3581576-B1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS FOR USE IN THE TREATMENT OF A PROLIFERATIVE DISEASE IN COMBINATION WITH A JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2022-01-26 | — | — | EP | disclosed |
| US-10781201-B2 | Benzimidazole derivative having JNK inhibitory activity and use thereof | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2020-09-22 | — | — | US | disclosed |
| US-20200039959-A1 | NOVEL BENZIMIDAZOLE DERIVATIVE HAVING JNK INHIBITORY ACTIVITY AND USE THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2020-02-06 | — | — | US | disclosed |
| EP-2970282-B1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE HOLDINGS CORP (US) | 2019-08-21 | — | — | EP | disclosed |
| US-10301291-B2 | Imidazole derivative having JNK inhibitory activity and use thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2019-05-28 | — | — | US | disclosed |
| US-20110021492-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-27 | — | — | US | disclosed |
| EP-2265601-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2010-12-29 | — | — | EP | disclosed |
| US-7767681-B2 | 2-Carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-08-03 | — | — | US | disclosed |
| US-7767681-B2 | 2-Carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-08-03 | — | — | US | disclosed |
| US-20100075990-A1 | MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | CAYMAN CHEMICAL COMPANY (US) | 2010-03-25 | — | — | US | disclosed |
| WO-2009114677-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-17 | — | — | WO | disclosed |
| US-20070179126-A1 | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-08-02 | — | — | US | disclosed |
| US-20070179126-A1 | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075990-A1 | MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | HPGDS, PTGIS, PTGES | ALDH1A1 2131/4885LMNA 2162/4885HPGD 13/4885 |
| US-20110021492-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | F11, F12, TFPI2 | ALDH1A1 2830/4885LMNA 605/4885HPGD 1220/4885 |
| US-10301291-B2 | Imidazole derivative having JNK inhibitory activity and use thereof | MAPKAPK2, MAPKAPK3, MAP3K7 | ALDH1A1 3334/4885LMNA 3982/4885HPGD 1425/4885 |
| US-20200039959-A1 | NOVEL BENZIMIDAZOLE DERIVATIVE HAVING JNK INHIBITORY ACTIVITY AND USE THEREOF | MAPKAPK3, MAPK3, MAP3K3 | ALDH1A1 3570/4885LMNA 3584/4885HPGD 2921/4885 |
| US-10781201-B2 | Benzimidazole derivative having JNK inhibitory activity and use thereof | MAPKAPK3, MAPK3, MAP3K3 | ALDH1A1 3337/4885LMNA 3370/4885HPGD 2588/4885 |
| US-20070179126-A1 | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | UGT2B7, PKD2, CYP2C19 | ALDH1A1 1008/4885LMNA 3869/4885HPGD 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.